Status:
COMPLETED
Nosocomial and Community Acquired Legionella Pneumophila Pneumonia.
Lead Sponsor:
Dr Philippe CLEVENBERGH
Conditions:
Legionnaires' Disease
Eligibility:
All Genders
18+ years
Brief Summary
Legionnaire's disease (LD) is a major cause of both community acquired and nosocomial pneumonia, with Legionella pneumophila serogroup A (Lp1) being the most virulent and the greatest cause of disease...
Eligibility Criteria
Inclusion
- All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years, from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre and the UZ Brussel Hospitals.
Exclusion
- Pregnant women.
Key Trial Info
Start Date :
August 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2019
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04106037
Start Date
August 13 2019
End Date
September 30 2019
Last Update
July 20 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020
2
CHU St Pierre Hospital
Brussels, Belgium, 1650
3
Universitair Zienkenhuis Brussel
Brussels, Belgium